Lupin Marks Strategic Entry into Chinese Pharmaceutical Market with Flu Treatment Approval
Indian pharmaceutical major Lupin Limited has officially entered the Chinese market following regulatory approval for its Oseltamivir oral suspension, a critical treatment for influenza. The National Medical Products Administration (NMPA) of China granted the authorization this week, marking the company’s first commercial footprint in the world’s second-largest pharmaceutical market. Expanding Global Footprint Lupin, headquartered in…